SIRS-Lab GmbH, a molecular diagnostics company based in Jena, Germany, and Pfizer Pharma GmbH, headquartered in Berlin, have announced a collaboration in the field of sepsis. The aim of this collaboration is to improve the outcome of patients with life-threatening infection, by using molecular diagnostic tests to achieve the earliest and most accurate targeting of anti-infective therapy.
“We are delighted to be working with Pfizer, one of the leaders in anti-infective therapy, and hope that this collaboration will help to improve the outcomes for patients with sepsis.”
The initial focus of the collaboration is on severe fungal blood-stream infections, with the goal to examine the impact of molecular test based diagnosis on the clinical outcome of patients with sepsis, as well as on the pharmacoeconomics of such interventions.
Barbara Staehelin, CEO of SIRS-Lab, said, "We are delighted to be working with Pfizer, one of the leaders in anti-infective therapy, and hope that this collaboration will help to improve the outcomes for patients with sepsis."
Coffee ring effect inspires breakthrough in rapid at-home tests for disease detection